Journal: Journal of the American Society of Nephrology

Article Title: Nasal Administration of Recombinant Rat α3(IV)NC1 Prevents the Development of Experimental Autoimmune Glomerulonephritis in the WKY Rat

doi: 10.1681/asn.2004121026

Figure Lengend Snippet: Figure 3. Effect of nasal administration of recombinant 3(IV)NC1 on circulating levels of IgG1 (A) and IgG2a (B) anti-3(IV)NC1 antibodies in groups of WKY rats (n 5 to 8) with EAG. Results shown represent the mean SD of each group at week 4 after immunization. *P 0.05, positive control versus 3(IV)NC1 250 g nasally.

Article Snippet: The isotypes of circulating anti- 3 antibodies were detected by mouse mAb specific for rat IgG1 and IgG2a (Serotec Ltd, Oxford, UK), followed by goat anti-mouse IgG (Serotec Ltd).

Techniques: Recombinant, Positive Control

Journal: Journal of the American Society of Nephrology

Article Title: Nasal Administration of Recombinant Rat α3(IV)NC1 Prevents the Development of Experimental Autoimmune Glomerulonephritis in the WKY Rat

doi: 10.1681/asn.2004121026

Figure Lengend Snippet: Figure 6. Effect of nasal administration of recombinant 3(IV)NC1 on deposits of IgG on the glomerular basement membrane (GBM) in groups of WKY rats (n 5 to 8) with EAG. Results shown represent the mean SD of each group at week 4 after immunization. *P 0.01, positive control versus 3(IV)NC1 100 g nasally; **P 0.001, positive control versus 3(IV)NC1 250 g nasally.

Article Snippet: The isotypes of circulating anti- 3 antibodies were detected by mouse mAb specific for rat IgG1 and IgG2a (Serotec Ltd, Oxford, UK), followed by goat anti-mouse IgG (Serotec Ltd).

Techniques: Recombinant, Membrane, Positive Control

Journal: Journal of the American Society of Nephrology

Article Title: Nasal Administration of Recombinant Rat α3(IV)NC1 Prevents the Development of Experimental Autoimmune Glomerulonephritis in the WKY Rat

doi: 10.1681/asn.2004121026

Figure Lengend Snippet: Figure 7. Direct immunofluorescence of kidney tissue at week 4 from WKY rats with EAG showing strong linear deposits of IgG on the GBM in a positive control animal (A) and marked reduction in the deposition of IgG on the GBM (B) in an animal that was given recombinant 3(IV)NC1 250 g nasally. Magni- fication, 300.

Article Snippet: The isotypes of circulating anti- 3 antibodies were detected by mouse mAb specific for rat IgG1 and IgG2a (Serotec Ltd, Oxford, UK), followed by goat anti-mouse IgG (Serotec Ltd).

Techniques: Immunofluorescence, Positive Control, Recombinant

Journal: ACS Applied Materials & Interfaces

Article Title: Augmenting Subunit-Vaccine-Induced Immunity through a Dual Strategy of Gold Nanoparticle Conjugation and Chitosan Microneedle-Mediated Sustained Delivery

doi: 10.1021/acsami.5c20082

Figure Lengend Snippet: Schematic of a dual-strategy for vaccine delivery. The vaccine delivery system consists of implantable CS MNs loaded with a GNP–OVA nanovaccine and attached to a removable PLA array patch (i.e., GNP–OVA MNs). Upon skin insertion of the CS MNs, the PLA array is detached, leaving the MNs embedded within the dermis to serve as an antigen depot, thereby enabling the sustained release of GNP–OVA through gradual degradation while promoting local immune cell recruitment. Internalized GNP–OVA nanovaccines promote the maturation of DCs and their migration to draining lymph nodes for antigen presentation, leading to enhanced OVA-specific immunoglobulin G production.

Article Snippet: HRP-conjugated secondary antibodies, including goat antirat IgG2a, goat antirat IgG1, and goat antirat IgG, were purchased from Novus Biologicals (Centennial, CO, USA).

Techniques: Migration, Immunopeptidomics

Journal: ACS Applied Materials & Interfaces

Article Title: Augmenting Subunit-Vaccine-Induced Immunity through a Dual Strategy of Gold Nanoparticle Conjugation and Chitosan Microneedle-Mediated Sustained Delivery

doi: 10.1021/acsami.5c20082

Figure Lengend Snippet: OVA-specific antibody responses induced by immunization in SD rats: (a) total IgG, (b) IgG1, and (c) IgG2a levels. SD rats were immunized through a subcutaneous injection with PBS, OVA, or GNP–OVA or through CS-MN-based delivery of GNP–OVA in accordance with a prime–boost schedule (Weeks 0 and 2). Serum samples were collected and analyzed for total IgG, IgG1, and IgG2a levels by using ELISA assays. Data are presented as mean ± standard deviation ( n = 5). * p < 0.05; ** p < 0.01; *** p < 0.001.

Article Snippet: HRP-conjugated secondary antibodies, including goat antirat IgG2a, goat antirat IgG1, and goat antirat IgG, were purchased from Novus Biologicals (Centennial, CO, USA).

Techniques: Injection, Enzyme-linked Immunosorbent Assay, Standard Deviation

Journal: Cellular and Molecular Life Sciences: CMLS

Article Title: Required minimal protein domain of flower for synaptobrevin2 endocytosis in cytotoxic T cells

doi: 10.1007/s00018-024-05528-1

Figure Lengend Snippet: Details of antibodies used in this study

Article Snippet: Anti-rat IgG2a, FITC , Novus Biologicals/#NB7124 , Goat, pc , 1:400 (FACS).

Techniques: Affinity Purification, Generated, Labeling, Purification, Control